Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:

• Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?

• Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.

• The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.

Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.

Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.
We break down the newest literature and answer:
Does immunotherapy really help with high-risk squamous cell carcinoma?
Are pemphigus patients getting more rituximab than they need?
Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?
Is the Mind.Px test actually helpful for picking a psoriasis biologic?
What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?
Which treatment factors predict scabies cure?
Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!
Hit play and stay on the cutting edge of medical dermatology!

1. Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma
2. Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial
3. Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium
4. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
5. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
6. Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab
7. Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.
We’re joined by CSU expert Dr. Jason Hawkes to discuss:

-How Dupixent is changing the game for CSU and why dermatologists are leading the charge

-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients

-How we explain to CSU patients that they don’t need allergy testing!

-Clinical pearls for work-up, navigating treatment guidelines, safety, and access

Perfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.

Hit play and stay ahead on the cutting edge of CSU care!

1. Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound

2. Remibrutinib in Chronic Spontaneous Urticaria

3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials